Major Shareholder Announcement
05 October 2024 - 3:55AM
Company Announcement
- Major shareholder announcement for Genmab
A/S
COPENHAGEN, Denmark; October 4, 2024 –
Genmab A/S (Nasdaq: GMAB) announces under
reference to Section 30 of the Danish Capital Markets Act that
Baillie Gifford & Co has informed us that, as of October 3,
2024, Baillie Gifford & Co held the voting rights to 3,301,530
shares in Genmab A/S, which amounts to 4.99% of the share capital
and voting rights in Genmab A/S.
About Genmab Genmab is an international
biotechnology company with a core purpose of guiding its
unstoppable team to strive toward improving the lives of patients
with innovative and differentiated antibody therapeutics. For 25
years, its passionate, innovative and collaborative team has
invented next-generation antibody technology platforms and
leveraged translational, quantitative and data sciences, resulting
in a proprietary pipeline including bispecific T-cell engagers,
antibody-drug conjugates, next-generation immune checkpoint
modulators and effector function-enhanced antibodies. By 2030,
Genmab’s vision is to transform the lives of people with cancer and
other serious diseases with knock-your-socks-off (KYSO®) antibody
medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please visit Genmab.com and
follow us on LinkedIn and
X.Contact: Marisol
Peron, Senior Vice President, Global Communications & Corporate
AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com This Company Announcement contains
forward looking statements. The words “believe,” “expect,”
“anticipate,” “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may
differ materially from any future results or performance expressed
or implied by such statements. The important factors that could
cause our actual results or performance to differ materially
include, among others, risks associated with preclinical and
clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety
issues, uncertainties related to product manufacturing, the lack of
market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products or technologies obsolete, and other factors. For a
further discussion of these risks, please refer to the risk
management sections in Genmab’s most recent financial reports,
which are available on www.genmab.com and the risk factors included
in Genmab’s most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission (SEC),
which are available at www.sec.gov. Genmab does not undertake any
obligation to update or revise forward looking statements in this
Company Announcement nor to confirm such statements to reflect
subsequent events or circumstances after the date made or in
relation to actual results, unless required by law. Genmab A/S
and/or its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped
Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®
and KYSO®.
Company Announcement no. 58 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 041024_CA58_Major Shareholder Baillie Gifford
Gen Digital (NASDAQ:GEN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Gen Digital (NASDAQ:GEN)
Historical Stock Chart
From Dec 2023 to Dec 2024